Innovent Announces First Participant Dosed in Phase 1 Clinical Study of IBI333 (VEGF-A/VEGF-C Bispecific Fusion Protein) in Patients with Neovascular Age-related Macular Degeneration
News Channel 11 wjhl.com,
ROCKVILLE, Md. and SUZHOU, China, Feb. 27, 2023 /PRNewswire/ -- Innovent Biologics, Inc.